FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads

FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter